Corbus Pharmaceuticals Holding Stock Performance
| CRBP Stock | USD 17.82 0.18 1.02% |
The firm shows a Beta (market volatility) of 1.57, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corbus Pharmaceuticals will likely underperform. At this point, Corbus Pharmaceuticals has a negative expected return of -1.15%. Please make sure to confirm Corbus Pharmaceuticals' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Corbus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Corbus Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 1.02 | Five Day Return (0.61) | Year To Date Return 181.52 | Ten Year Return (83.45) | All Time Return (80.20) |
Last Split Factor 1:30 | Last Split Date 2023-02-14 |
1 | Disposition of 1770 shares by Yuval Cohen of Corbus Pharmaceuticals at 14.1 subject to Rule 16b-3 | 09/06/2024 |
2 | Bullish Wednesday For Marijuana Stocks - Australis Capital, Leafbuyer Techs Among Top Gainers | 09/18/2024 |
3 | Cormorant asset management buys 7m in Corbus Pharmaceuticals stock | 09/24/2024 |
4 | Point72 Asset Management L.P. Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. - MarketBeat | 10/01/2024 |
5 | Acquisition by Cormorant Asset Management, Lp of 47564 shares of Corbus Pharmaceuticals at 21.474 subject to Rule 16b-3 | 10/09/2024 |
6 | Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC | 10/16/2024 |
7 | Corbus Pharmaceuticals Holdings, Inc. Short Interest Update | 11/01/2024 |
8 | Vanguard Group Incs Strategic Acquisition in Corbus Pharmaceuticals | 11/05/2024 |
9 | Corbus Pharmaceuticals Q3 Earnings Snapshot | 11/07/2024 |
10 | OrbiMed Advisors LLC Acquires New Stake in Corbus Pharmaceuticals Holdings Inc | 11/15/2024 |
11 | Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference | 11/21/2024 |
12 | Corbus Pharmaceuticals Holdings, Inc. An Oversold Healthcare Stock to Invest In Now | 11/26/2024 |
| Begin Period Cash Flow | 17.7 M |
Corbus |
Corbus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,569 in Corbus Pharmaceuticals Holding on September 3, 2024 and sell it today you would lose (3,787) from holding Corbus Pharmaceuticals Holding or give up 68.0% of portfolio value over 90 days. Corbus Pharmaceuticals Holding is currently does not generate positive expected returns and assumes 8.7959% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Corbus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corbus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corbus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Corbus Pharmaceuticals Holding, and traders can use it to determine the average amount a Corbus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1305
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRBP |
Estimated Market Risk
| 8.8 actual daily | 78 78% of assets are less volatile |
Expected Return
| -1.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Corbus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corbus Pharmaceuticals by adding Corbus Pharmaceuticals to a well-diversified portfolio.
Corbus Pharmaceuticals Fundamentals Growth
Corbus Stock prices reflect investors' perceptions of the future prospects and financial health of Corbus Pharmaceuticals, and Corbus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corbus Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 61.29 M | ||||
| Shares Outstanding | 12.18 M | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 163.32 X | ||||
| Gross Profit | (16.14 M) | ||||
| EBITDA | (44.44 M) | ||||
| Net Income | (44.6 M) | ||||
| Cash And Equivalents | 66.23 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 20.88 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 12.36 X | ||||
| Cash Flow From Operations | (36.1 M) | ||||
| Earnings Per Share | (4.71) X | ||||
| Market Capitalization | 217.04 M | ||||
| Total Asset | 28.27 M | ||||
| Retained Earnings | (436.68 M) | ||||
| Working Capital | (8.35 M) | ||||
| Current Asset | 12.71 M | ||||
| Current Liabilities | 3.63 M | ||||
About Corbus Pharmaceuticals Performance
Assessing Corbus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Corbus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corbus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.2 K | 1.2 K | |
| Return On Tangible Assets | (1.58) | (1.66) | |
| Return On Capital Employed | 12.45 | 13.07 | |
| Return On Assets | (1.58) | (1.66) | |
| Return On Equity | 6.46 | 6.78 |
Things to note about Corbus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Corbus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corbus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corbus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corbus Pharmaceuticals has high historical volatility and very poor performance | |
| Corbus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (44.6 M) with loss before overhead, payroll, taxes, and interest of (16.14 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from insidermonkey.com: Corbus Pharmaceuticals Holdings, Inc. An Oversold Healthcare Stock to Invest In Now |
- Analyzing Corbus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corbus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Corbus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corbus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corbus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corbus Pharmaceuticals' stock. These opinions can provide insight into Corbus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.